CN106692204A - Probiotics composition for alleviating or improving pelvic inflammatory diseases and preparation method thereof - Google Patents
Probiotics composition for alleviating or improving pelvic inflammatory diseases and preparation method thereof Download PDFInfo
- Publication number
- CN106692204A CN106692204A CN201710141644.6A CN201710141644A CN106692204A CN 106692204 A CN106692204 A CN 106692204A CN 201710141644 A CN201710141644 A CN 201710141644A CN 106692204 A CN106692204 A CN 106692204A
- Authority
- CN
- China
- Prior art keywords
- parts
- probiotics
- lactobacillus
- probiotic composition
- drinking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 108
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 36
- 235000008216 herbs Nutrition 0.000 claims abstract description 33
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 22
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 22
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 22
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 21
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 17
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 55
- 230000000529 probiotic effect Effects 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 35
- 230000035622 drinking Effects 0.000 claims description 32
- 230000010354 integration Effects 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 31
- 241000894006 Bacteria Species 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 11
- 241000522254 Cassia Species 0.000 claims description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 10
- 244000197580 Poria cocos Species 0.000 claims description 10
- 235000008599 Poria cocos Nutrition 0.000 claims description 10
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 10
- 241000220317 Rosa Species 0.000 claims description 10
- 241000245665 Taraxacum Species 0.000 claims description 10
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 10
- 244000144730 Amygdalus persica Species 0.000 claims description 9
- 235000013717 Houttuynia Nutrition 0.000 claims description 9
- 240000000691 Houttuynia cordata Species 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 239000011885 synergistic combination Substances 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- 240000000171 Crataegus monogyna Species 0.000 claims 3
- 241000251468 Actinopterygii Species 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000020995 raw meat Nutrition 0.000 claims 1
- 210000005000 reproductive tract Anatomy 0.000 abstract description 13
- 230000036039 immunity Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000008485 antagonism Effects 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 210000004291 uterus Anatomy 0.000 description 15
- 229940039696 lactobacillus Drugs 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 241001092040 Crataegus Species 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000003958 fumigation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 210000002229 urogenital system Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000028685 Asherman syndrome Diseases 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000206591 Peptococcus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010054824 Tubo-ovarian abscess Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000005125 simple columnar epithelium Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a probiotics composition for alleviating or improving pelvic inflammatory diseases. The probiotics composition is prepared from lactobacillus rhamnosus, lactobacillus acidophilus and lactobacillus plantarum. In the probiotics composition, the total quantity of the probiotics is 8.0*10<9> to 4.0*10<10> cfu/g. The probiotics composition is synergistically combined with medicinal and herbal Chinese herbs to prepare a probiotics Chinese herbal preparation. Further, the probiotics composition, the medicinal and edible Chinese herb extract, prebiotics and the like are compounded to prepare a product for alleviating or improving the pelvic inflammatory diseases. The probiotics composition can improve the immunity of the body, can promote the development of physiologic normal probiotics group in genital tract can be promoted; and by virtue of bological antagonism, pathogenic bacteria is indirectly controlled and killed to adjust a micro-ecological balance in the genital tract, so that the pelvic inflammatory diseases are alleviated or improved.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of probiotic composition alleviated or improve pelvic inflammation
And preparation method thereof.
Background technology
Pelvic inflammatory disease (pelvic inflammatory disease, PID) is caused by genital inflammation in women
One group of disease, including endometritis, salpingitis, tubo-ovarian abscess and pelvic peritonitis.Inflammation can be confined to one
Individual position, it is also possible to while involve several positions, it is most commonly seen with salpingitis, salpingo-oothecitis.
Pelvic infecton is the common disease for endangering WomanHealth, and the microbial state treatment (dyshiosis) of vagina causes vagina intrinsic
The endogenous chance infection that bacterium is up and causes is the main cause of pelvic infecton.In genital tract main resident bacterium have lactobacillus,
MRSE, Escherichia coli, corynebacteria, streptococcus fecalis, mycoplasma, Candida albicans, peptococcus, bacteroid etc..
Wherein lactobacillus is the most resident bacterium of most important, quantity in vagina normal flora, accounts for more than 95%, is normal dominant bacteria.
Probiotics is not only closely bound up with gastrointestinal health, and some specific probiotics strains also help female genitourinary system and are good for
Health, can prevent and treat female genitourinary system infection such as bacterial vaginitis, pelvic infecton and other related complications.It is strong
Seldom, basin intracavity liquid substantially increases the basin intracavity liquid of health during inflammatory disorderses, and most pelvic infecton are by the thin of intravaginal
Caused by bacterium is along the up infection pelvic organ of mucous membrane, there are a large amount of anaerobic bacterias in normal vagina, once environment changes or condition is favourable,
Such as local blood supply insufficiency；In the presence of damage or slough；There is the foreign matter such as intrauterine contraceptive device；Exogenous microbial growth and breeding
The bacterium of disorganization, intravaginal is caused such as to be deposited with aerobic bacteria simultaneously along positions such as the up uterine cavity of mucous membrane, fallopian tubals
, more to anaerobic bacteria growth and breeding provide good anaerobic condition, cause inflammation to occur, the severe degree of inflammatory reaction can
Reflected with by the expression quantity of some cell factors height.
Cell factor is the polypeptide of a class transmitting inflammation and immune response for being synthesized and being secreted by immunocompetent cell etc.
Albumen, is produced by lymphocyte, monocyte, macrophage, fibroblast etc., is risen in host resists tissue-damaging process
Important function, is related to the complex process of many physiology and pathology in body, can activated lymphocyte, regulation lymphocyte and other
Metabolism and the function of the growth and differentiation of cell, enhancing immune response and inflammatory cell, the generation with clinical many important diseases
It is closely related with lapsing to.IL-2 is the cell factor with various biological activity, mainly by helper T lymphocyte and macrophage
Secretion, the effect of, increase body anti-infection ability immune with regulation.Used as a kind of important cell factor, IL-2 is thin with T
Born of the same parents, B cell, the IL-2 acceptors of onthe surface of monocytes are combined, and T cell can be caused to breed, and promote cytotoxic T cell lethal effect,
Enhancing natural killer cell activity, promotes the immunoglobulins such as B cell IgG secretion, therefore has in terms of immunological regulation important
Meaning.The activation degree and host immune system that the height of IL-2 levels reflects host's T lymphocytes from a side are clear
Except the capacity of water of itself aging DC, autologous denaturation and damaging cells.IL-6 is a kind of important inflammatory cytokine,
It is one of outstanding feature of inflammatory reaction, there is the scorching activity of strong cause, content increases during inflammation, can influence the propagation point of B cell
Change, played an important role in acute cellular rejection and inflammatory reaction.It can be done directly on vascular endothelial cell, increase its permeability
Plus, cause a large amount of inflammatories to ooze out, can be cooperateed with tumor necrosis factor α etc., constitute inflammatory mediator network.The generation meeting of excessive IL-6
Cause violent immune response, body is caused damage.Research shows that the IL-6 of high concentration can substantially suppress T lymphocytes IL-
The synthesis of 2 and IL-2R.A kind of important cytokine that TNF-α is produced as activated mononuclear-macrophage, in infectious diseases
And aspect of inflammation, vascular endothelial cell can be stimulated to express adhesion molecule, stimulate monokaryon-macrophage and the secretion of other cells to become
The property changed cell factor, causes leucocyte to be assembled in inflammation part, promotes inflammatory reaction, and appropriate TNF-α promotes body's immunity,
The pathogenic original of invasion is killed and eliminated to regulation panimmunity cell jointly, and the excessive TNF-α of overreaction is then produced acutely immune
Reaction, is presented toxic action, and body is caused damage.
Mainly have for the treatment method of pelvic inflammatory disease at present：Antibiotic therapy, Chinese herbal fumigation and washing therapy and Tiny ecosystem
Therapy etc., wherein, antibiotic is the class medicine being most widely used in current clinical treatment infectious diseases.However, antibiosis
Element destroys vagina normal flora while pathogenic bacteria are suppressed, and microorganism advantage is changed, and occurs largely having resistance
The pathogenic microorganism of property, once subinfection again, will have a strong impact on the curative effect of antibiotic.
Chinese herbal fumigation and washing therapy makes the efficacy of a drug directly act on affected part by local excitation, eliminates symptom, solves focus.After lead to
Cross skin, hole key, acupuncture points on the human body the absorption of the smell of medicine, channels and collaterals are adjusted, the defeated cloth of internal organs and the integral medicinal caused by medicine irritation
Reason effect and reach integrally-regulated, be allowed to play a role, promote negative and positive to keep relative equilibrium.Modern doctor treats use more than this disease
The method of removing damp-heat stagnation resolvation, but some patient's ferritic cold of insufficiency type, the product of long-term mistake bitter cold or abuse of antibiotics equivalent damage are positive in addition
Gas, causes yin-cold excess, cold blood stasis.
Tiny ecosystem therapy：Its essence is that, to foster normal flora, antagonism causes a disease or conditioned pathogen, adjusts and recover micro- life
A kind of prevention and treatment method for the purpose of state balance.Microecologic regulator is under microecology theoretical direction, to correct micro- life
Unbalance, the holding microecological balance of state, improves probiotics (microorganism) and its generation of body health level or the state that improves health
Thank to the product of product and growth helping matter.
Go deep into to RTI RTI (reproductive tract infection) research, people by
The ecological balance for maintaining vagina normal flora is gradually recognized, the leading position for keeping vagina beneficial bacterium-lactobacillus is preventing and treating reproduction
The effective ways of road infectious diseases.Currently, as the toxic and side effect of antibiotic and the abuse of antibiotic cause a large amount of resistances
The appearance of flora and suprainfection so that dominance of the antibiotic in terms of infectious diseases is treated increasingly is challenged,
Tiny ecosystem therapy is just causing the attention of medical personal.Therefore, if microecologic regulator can be widely used in clinic, will be
Preventing and treating women's genital tract infection opens up a new approach, also will provide safely and effectively health care good medicine for numerous women.But mesh
It is preceding to be not yet related to the report that probiotics has alleviation or improves pelvic infecton aspect effect.
The content of the invention
For above-mentioned the deficiencies in the prior art, it is an object of the invention to provide a kind of benefit alleviated or improve pelvic inflammation
Raw bacteria composition.Probiotic composition of the invention can strengthen immunity of organisms, and physiological in genital tract can be promoted normal
The development of beneficial flora, by biological antagonist, is indirectly controlled and eliminates pathogen, is put down with adjusting the Tiny ecosystem in genital tract
Weighing apparatus, so as to realize alleviating or improving pelvic inflammation.
Another object of the present invention is to provide the probiotics Chinese medicine preparation alleviated or improve pelvic inflammation, by will be prebiotic
Bacterium and Chinese medicine use in conjunction, synergy reach the purpose of Bian Zhibian tune, significantly enhance the treatment curative effect to pelvic infecton.
To achieve the above object, the present invention is adopted the following technical scheme that：
The first aspect of the present invention, there is provided the probiotic composition of a kind of alleviation or improvement pelvic inflammation, by rhamnose breast
Bacillus, lactobacillus acidophilus and Lactobacillus plantarum composition；
In the probiotic composition, the total quantity of probiotics is 8.0 × 109-4.0×1010cfu/g。
Preferably, in the probiotic composition, the mass ratio of Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum
It is 2:1:1.
It is further preferred that the lactobacillus acidophilus is deposit number CCTCC NO:The lactobacillus acidophilus of M2015129
(Lactobacillus acidophilus)BLCC2-0024；The Lactobacillus plantarum is deposit number CCTCC M2010150
Lactobacillus plantarum LP.
The present invention also provides the preparation method of above-mentioned probiotic composition, and step is as follows：
(1) after Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum being activated through culture medium respectively, it is inoculated in fermentation
In nutrient solution, 37 DEG C of constant temperature quiescent cultures make cell concentration reach exponential phase 4.0 × 109-8.0×109cfu/ml；
(2) zymotic fluid is centrifuged respectively, abandons supernatant, obtain Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum
Bacterium mud；
(3) bacterium mud is well mixed with freeze drying protectant, freeze-drying is obtained final product.
The second aspect of the present invention, there is provided the probiotics Chinese medicine preparation of a kind of alleviation or improvement pelvic inflammation, by above-mentioned benefit
Raw bacteria composition and the integration of drinking and medicinal herbs Chinese medical extract synergistic combination with treatment pelvic infecton effect are formed.
The integration of drinking and medicinal herbs Chinese medical extract is made up of the bulk drug of following weight portion：
Radix Angelicae Sinensis 2-3 parts, peach kernel 2-5 parts, raw hawthorn 6-12 parts, Poria cocos 10-15 parts, Chinese cassia tree 2-3 parts, Radix Glycyrrhizae 3-9 parts, rose
3-10 parts, dandelion 6-10 parts, cordate houttuynia 15-30 parts of flower.
Preferably, the integration of drinking and medicinal herbs Chinese medical extract is made up of the bulk drug of following weight portion：
2 parts of Radix Angelicae Sinensis, 3 parts of peach kernel, 8 parts of raw hawthorn, 10 parts of Poria cocos, 2 parts of Chinese cassia tree, 6 parts of Radix Glycyrrhizae, 6 parts of rose, dandelion 6
Part, 15 parts of cordate houttuynia.
The present invention also provides the preparation method of above-mentioned integration of drinking and medicinal herbs Chinese medical extract, and step is as follows：
Radix Angelicae Sinensis, peach kernel, raw hawthorn, Poria cocos, Chinese cassia tree, Radix Glycyrrhizae, rose, dandelion, cordate houttuynia are placed in 8-10 times of water
Immersion 30-60min, decocts, and water continues to decoct 20-40min after opening, and is filtrated to get the first filtrate；The dregs of a decoction carry out two with 6-8 times of water
Secondary decoction, water continues to decoct 20-40min after opening, and is filtrated to get the second filtrate and is well mixed with the first filtrate, is concentrated into solid content
Content is more than 30%, and spray drying is crushed, and sieving obtains final product integration of drinking and medicinal herbs Chinese medical extract；
Preferably, in above-mentioned probiotics Chinese medicine preparation, the weight of the probiotic composition and integration of drinking and medicinal herbs Chinese medical extract
Amount is than being (2-10)：(20-30).
Above-mentioned probiotic composition and/or probiotics Chinese medicine preparation are in the product alleviated or improve pelvic inflammation is prepared
Purposes is also protection scope of the present invention.
In such use, the product is medicine, food or health products.
The third aspect of the present invention, there is provided the product of a kind of alleviation or improvement pelvic inflammation, by following mass percent
Component is constituted：
Probiotic composition 2-10%, integration of drinking and medicinal herbs Chinese medical extract 20-30%, prebiotics 50-60%, auxiliary material filler
5-10%.
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, institute
Prebiotics is stated by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 5:3:1 composition.
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
The present invention also provides above-mentioned alleviation or improves the preparation method of the product of pelvic inflammation, and step is as follows：
(1) probiotic composition and integration of drinking and medicinal herbs Chinese medical extract are prepared as stated above；
(2) probiotic composition, integration of drinking and medicinal herbs Chinese medical extract, prebiotics and auxiliary material filler are well mixed, are obtained final product.
Beneficial effects of the present invention：
(1) it is provided by the present invention to strengthen body with the probiotic composition for alleviating or improving pelvic inflammation function
Immunity, and can promote the development of the normal beneficial flora of physiological in genital tract, by biological antagonist, be indirectly controlled and eliminate
Pathogen, to adjust the microecological balance in genital tract, so as to realize alleviating or improving pelvic inflammation.
(2) probiotics Chinese medicine preparation provided by the present invention, is by above-mentioned probiotic composition and with treatment pelvic cavity
The integration of drinking and medicinal herbs Chinese medicine synergistic combination of scorching effect is formed, wherein, the extract of integration of drinking and medicinal herbs Chinese medicine is adjusted as a kind of Tiny ecosystem
Agent from strengthen the body resistance to consolidate the constitution and eliminating evil two in terms of play a role, both promoted the recovery of lactobacillus in genital tract, improve immunity of organisms, and
Pathogenic microorganisms is killed and suppresses to adjust genital tract imbalance flora；Probiotics can preferably resolve into Chinese medical extract small
Molecular substance, is conducive to the absorption of enteron aisle, Chinese medicine and probiotics reasonable compatibility, experiment proves that, Bian Zhibian tune can be reached
Purpose, plays a part of enhancing effect, realizes the perfect adaptation of probiotics and Chinese medicine.
(3) present invention is provided alleviation or the product of improvement pelvic inflammation, are same by above-mentioned probiotic composition, medicine food
Source Chinese medicine, prebiotics and auxiliary material filler are prepared from, and on the basis of probiotics, Chinese medicine synergy, increased again prebiotic
First component, prebiotics as a kind of dietary supplements, by the growth for stimulating bacterium in a kind of or a small number of kind of bacterium colony of selectivity
With activity, and to host produce wholesome effect.The prebiotics component added in the present invention can be with probiotic combinations produce
Raw further synergy, so as to be more beneficial for improvement and mitigation to pelvic infecton symptom.
(4) product of alleviation of the invention or improvement pelvic inflammation, preparation process is simple, each active ingredient in Chinese medicine
Loss is less, safe, it is ensured that the stability between product batches.
Specific embodiment
It is noted that described further below is all exemplary, it is intended to provide further instruction to the application.Unless another
Indicate, all technologies used herein and scientific terminology are with usual with the application person of an ordinary skill in the technical field
The identical meanings of understanding.
It should be noted that term used herein above is merely to describe specific embodiment, and be not intended to restricted root
According to the illustrative embodiments of the application.As used herein, unless the context clearly indicates otherwise, otherwise singulative
Be also intended to include plural form, additionally, it should be understood that, when in this manual use term "comprising" and/or " bag
Include " when, it indicates existing characteristics, step, operation, device, component and/or combinations thereof.
As background technology is introduced, lacking can alleviate or improve the Tiny ecosystem regulation of pelvic inflammation in the prior art
Agent, in order to solve technical problem as above, present applicant proposes a kind of probiotic composition alleviated or improve pelvic inflammation, should
Probiotic composition can strengthen immunity of organisms, and can promote the development of the normal beneficial flora of physiological in genital tract, pass through
Biological antagonist, is indirectly controlled and eliminates pathogen, to adjust the microecological balance in genital tract, so as to realize alleviating or improve
Pelvic inflammation.
In a kind of embodiment of the application, there is provided a kind of probiotic composition alleviated or improve pelvic inflammation,
It is made up of Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum；In the probiotic composition, the total quantity of probiotics is
8.0×109-4.0×1010cfu/g。
As one kind preferred embodiment, in the probiotic composition, Lactobacillus rhamnosus, lactobacillus acidophilus and plant
The mass ratio of thing lactobacillus is 2:1:1.
Because can also there is larger difference in the performance of the bacterial strain of the same race of separate sources, therefore, the application is in process of the test
Probiotics that species, same but different separation also to the probiotics in probiotic composition are originated and combinations thereof is adjusted
It is whole, as a result find, it is CCTCC NO with deposit number relative to other species or the probiotic combinations in source:M2015129's
Lactobacillus acidophilus (Lactobacillus acidophilus) BLCC2-0024, deposit number are the plant of CCTCC M2010150
The effect that thing lactobacillus LP and Lactobacillus rhamnosus are compounded is best.
The deposit number is CCTCC NO:Lactobacillus acidophilus (the Lactobacillus of M2015129
Acidophilus) BLCC2-0024 is preserved in China typical culture collection center on March 18th, 2015, and records special
In sharp " a kind of hypoglycemic probiotics preparation and preparation method thereof " (CN105039217A), prior art is constituted, therefore no longer provide
Preservation is proved.Bacterial strain function involved at present mainly has hypoglycemic and alleviates the elderly's YIN-deficiency type constipation, there is not yet it is used
In the report for the treatment of pelvic inflammation.
The deposit number is preserved in China on June 21st, 2010 for the Lactobacillus plantarum LP of CCTCC M2010150
Type Tissue Collection, and record patent " a kind of to can be used for the lactic acid bacteria of biological preservation and its application "
(CN101914475A) in, prior art is constituted, therefore no longer providing preservation proves.Bacterial strain function involved at present is mainly
For the anti-corrosive fresh-keeping of fruit, there is not yet it is used to treat the report of pelvic inflammation.
The Lactobacillus rhamnosus is conventional commercially available prod.
The selected above-mentioned three plants of bacterium of the application can promote the development of the normal beneficial flora of physiological in genital tract, pass through
Biological antagonist, is indirectly controlled and eliminates pathogen, such as Escherichia coli, staphylococcus aureus, to adjust in genital tract
Microecological balance；The immunocompetence and regulating intestinal canal system of body can also be strengthened simultaneously, health body-building effect is played, so that real
Now alleviate or improve pelvic inflammation.
In the another embodiment of the application, there is provided a kind of probiotics Chinese medicine system alleviated or improve pelvic inflammation
Agent, is formed by above-mentioned probiotic composition with the integration of drinking and medicinal herbs Chinese medical extract synergistic combination with treatment pelvic infecton effect.
The integration of drinking and medicinal herbs Chinese medical extract is made up of the bulk drug of following weight portion：
Radix Angelicae Sinensis 2-3 parts, peach kernel 2-5 parts, raw hawthorn 6-12 parts, Poria cocos 10-15 parts, Chinese cassia tree 2-3 parts, Radix Glycyrrhizae 3-9 parts, rose
3-10 parts, dandelion 6-10 parts, cordate houttuynia 15-30 parts of flower.
The preparation method of the integration of drinking and medicinal herbs Chinese medical extract is as follows：
Radix Angelicae Sinensis, peach kernel, raw hawthorn, Poria cocos, Chinese cassia tree, Radix Glycyrrhizae, rose, dandelion, cordate houttuynia are placed in 8-10 times of water
Immersion 30-60min, decocts, and water continues to decoct 20-40min after opening, and is filtrated to get the first filtrate；The dregs of a decoction carry out two with 6-8 times of water
Secondary decoction, water continues to decoct 20-40min after opening, and is filtrated to get the second filtrate and is well mixed with the first filtrate, is concentrated into solid content
Content is more than 30%, and spray drying is crushed, and sieving obtains final product integration of drinking and medicinal herbs Chinese medical extract.
As one kind preferred embodiment, in above-mentioned probiotics Chinese medicine preparation, the probiotic composition and medicine food are same
The weight ratio of source Chinese medical extract is (2-10)：(20-30).
Chinese medicine containing sugar, fat, amino acid and trace element, can provide necessary nutriment for body in itself.Animal
Experiment and clinical observation prove that part Chinese herbal medicine has fosters normal flora growth, adjustment flora imbalance, improves colonization resistance
Effect, is a kind of preferable microecologic regulator.Chinese medicine may from strengthen the body resistance to consolidate the constitution and eliminating evil two in terms of play a role, both promote the moon
The recovery of lactobacillus in road, improves immunity of organisms, kills and suppress pathogenic microorganisms again to adjust vagina imbalance flora, and this can
Can be that its curative effect is relatively stablized, be difficult one of the reason for recurring.Chinese medicine preparation is combined as microecologic regulator with active bacteria formulation should
With, the purpose of Bian Zhibian tune is reached, enhancing effect can be played a part of.
In the prescription of the integration of drinking and medicinal herbs Chinese medical extract of the application：
Radix Angelicae Sinensis has a benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, moisturize laxation, anticancer, it is anti-ageing anti-old, immune the effect of, basin can be alleviated
The disease of chamber inflammation stomachache；Peach kernel has promoting blood circulation, relaxes bowel, relieving cough and asthma effect；Hawthorn has relieving dyspepsia, promoting blood circulationization
The good medicine of phlegm；Poria cocos has clearing damp and promoting diuresis, invigorating the spleen, effect of calming heart；Chinese cassia tree has complement sun, warming spleen and stomach, removing internal cold, promoting blood circulation
Effect；The symptoms such as Radix Glycyrrhizae indication is clearing heat and detoxicating, gastral cavity abdomen；Rose nature and flavor are sweet, slight bitter, temperature.Return liver, the spleen channel.With row
Gas solution is strongly fragrant, and blood, the effect of analgesic；The effect of dandelion has clearing heat and detoxicating, is the good medicine of gynecological disease；Cordate houttuynia taste is pungent,
It is cold, return lung warp.Can clearing heat and detoxicating, the effect for the treatment of sore, promoting urination and removing dampness, clearing away heat to cure dysentery, stomach strengthening and digestion promoting of subsiding a swelling；Play foster altogether in full side
Blood stagnation resolvation, promoting blood circulation and detoxication is dredged through dredging collateral, and regulating qi-flowing for strengthening spleen, constitutional effect fundamentally alleviates pelvic infecton symptom.
And Chinese medical extract can be resolved into preferably probiotic composition small-molecule substance, be conducive to the suction of enteron aisle
Receive, it is achieved thereby that the perfect adaptation of probiotics and Chinese medicine.In the probiotics Chinese medicine preparation of the application, the Chinese medicine group of integration of drinking and medicinal herbs
Divide and probiotic composition compatibility is reasonable, experiment proves that, the purpose of Bian Zhibian tune can be reached, play a part of enhancing effect.
Through analysis, the effect that pelvic inflammation is alleviated or improved to probiotics Chinese medicine preparation of the invention may be by improving body
The expression of immunocompetence, regulation inflammation body serum cytokine-expressing, and the regulation pelvic tissue local inflammation factor, so that
Suppress the chemotactic response of TNF-α and IL-6 mediations, and by raising IL-2 expression inhibiting inflammatory reactions, mitigate inflammation in body tissues
Damage, so as to reach the effect alleviated or improve pelvic inflammation.
In the yet another embodiment of the application, there is provided a kind of product alleviated or improve pelvic inflammation, by following
The component composition of mass percent：
Probiotic composition 2-10%, integration of drinking and medicinal herbs Chinese medical extract 20-30%, prebiotics 50-60%, auxiliary material filler
5-10%.
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, institute
Prebiotics is stated by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 5:3:1 composition.
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
The present invention also provides above-mentioned alleviation or improves the preparation method of the product of pelvic inflammation, and step is as follows：
(1) probiotic composition and integration of drinking and medicinal herbs Chinese medical extract are prepared as stated above；
(2) probiotic composition, integration of drinking and medicinal herbs Chinese medical extract, prebiotics and auxiliary material filler are well mixed, are obtained final product.
In order that obtaining those skilled in the art can clearly understand the technical scheme of the application, below with reference to tool
The embodiment of body describes the technical scheme of the application in detail.
Test material used is the conventional test material in this area in the embodiment of the present invention, can be by commercial channel
It is commercially available.
Embodiment 1：The preparation of the freeze-dried powder of probiotics
1) by three plants of lactobacillus, (deposit number is CCTCC NO respectively:The lactobacillus acidophilus of M2015129
(Lactobacillus acidophilus) BLCC2-0024, deposit number are the Lactobacillus plantarum LP of CCTCC M2010150
And Lactobacillus rhamnosus) through culture medium activate after, be inoculated in fermentation culture, 37 DEG C of constant temperature quiescent cultures make cell concentration
Reach exponential phase 4.0 × 109-8.0×109cfu/ml；
The preparation of lactobacillus seed liquor：Culture presevation pipe is taken out, being rule respectively with lactic acid bacteria inclined-plane solid medium is carried out
Recovery, 37 degree of culture 24-36h.Bacterium colony violet staining microscopy on picking slant medium, is brevibacterium or bacillus long.Choose
Take in colony inoculation 100mL lactic acid bacteria culturing mediums, 24h is cultivated in 37 degree of incubators.Seed is connect using the inoculum concentration of 2-5%
Plant into the big triangular flasks of 3L, 37 degree of culture 24-36h detect its bacterial concentration, and bacterial content is more than 2,000,000,000/milliliter, you can used as breast
Bacillus liquid spawn is inoculated with.Wherein described MRS culture mediums：Glucose 2.0%, ammonium citrate 0.2%, sodium acetate 0.5%, phosphorus
Sour hydrogen dipotassium 0.5%, manganese sulfate 0.02%, magnesium sulfate 0.05%, peptone 1.0%, beef extract 1.0%, yeast extract 0.5%,
Tween 80 0.1%, adjusts pH to 6.0；Solid medium adds 1.5% agar powder.Medium sterilization condition is：0.10-
0.15MPa, 121 DEG C of sterilizing 20min.
2) by step 1) in various zymotic fluids be centrifuged respectively, abandon supernatant, obtain bacterium mud；
3) freeze drying protectant is prepared；Wherein the formula of freeze drying protectant constitutes and is：It is skimmed milk power 25g, sucrose 8g, edible sweet
Oily 1g, distilled water 100mL.
4) bacterium mud and freeze drying protectant are well mixed, mixture pre-freeze, then vacuum freeze drying is made with embedding
The freeze-dried powder of the active probiotic of layer.
Embodiment 2：The preparation of integration of drinking and medicinal herbs Chinese medical extract
1) according to preferred weight part：Radix Angelicae Sinensis 2g, peach kernel 3g, raw hawthorn 8g, Poria cocos 10g, Chinese cassia tree 2g, Radix Glycyrrhizae 6g, rose
6g, dandelion 6g, cordate houttuynia 15g；
2) mixture is placed in 10 times of water and soaks 40min, decocted, water continues to decoct 30min after opening, and is filtrated to get first
Filtrate；The dregs of a decoction carry out secondary decoction with 8 times of water, and water continues to decoct 30min after opening, and is filtrated to get the second filtrate and is mixed with the first filtrate
Close uniform, be more than 30% to solid content by vacuum decompression Rotary Evaporators concentrated traditional Chinese medicine liquid, enter spray dryer,
140 DEG C of EAT control, 90 DEG C of leaving air temp, 45 revs/min of atomizer rotating speed, charging rate is 5ml/ minutes, must be sprayed
Xeraphium, crushes, and crosses 100 mesh above sieves, obtains final product integration of drinking and medicinal herbs Chinese medical extract.
Embodiment 3：Preparation with alleviation or the probiotic composition for improving pelvic inflammation
Freeze-dry Powder of Probioctics prepared by embodiment 1, i.e. Lactobacillus rhamnosus, lactobacillus acidophilus, 3 kinds of breasts of Lactobacillus plantarum
Sour bacterium is 2 according to mass ratio:1:1 ratio carries out science compounding, is well mixed, and obtains final product with alleviation or improves pelvic inflammation
Probiotic composition.
Embodiment 4：Preparation with alleviation or the probiotics Chinese medicine preparation for improving pelvic inflammation
Integration of drinking and medicinal herbs Chinese medical extract prepared by probiotic composition and embodiment 2 prepared by embodiment 3 crosses 100 respectively
Mesh above sieve, and weigh standby, according to mass ratio it is 8 by probiotic composition and integration of drinking and medicinal herbs Chinese medical extract：30 are carried out
Dispensing.Each material will fully be mixed in mixer to uniform color above, no color differnece obtains having and alleviate or improvement pelvic cavity
The probiotics Chinese medicine preparation of inflammation function.
Embodiment 5：Preparation with alleviation or the product for improving pelvic inflammation
Integration of drinking and medicinal herbs Chinese medical extract prepared by the freeze-dried powder and embodiment 2 of probiotics prepared by embodiment 1 mistake respectively
100 mesh above sieves, and weigh standby；It is by mass percentage probiotics dry powder 8%, Chinese medical extract 30%, prebiotics
55%, the ratio of auxiliary material filler 7% carries out dispensing.Each material will fully be mixed to uniform color, nothing in mixer above
Aberration, that is, obtain having the product alleviated or improve pelvic inflammation function.
The prebiotics is by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 5:3:1 composition.
The auxiliary material filler is citric acid.
Embodiment 6：To the improvement result of pelvic infecton model mice pelvic infecton symptom
1) foundation of pelvic infecton mouse model
Animal prepares：From the Kun ming white mouse without genital diseases, mouse pelvic infecton model is built.
Animal opens abdomen：According to the chloraldurate of 1% intraperitoneal injection 4% of Mouse Weight, general anesthesia, by mouse after several minutes
It is placed on fixed station, subtracts belly wool, 75% ethanol disinfection skin takes the scissors tweezers of sterilizing, cuts off mouse lower abdomen skin
And muscle layer, the otch of about 1cm, expose abdominal cavity.
Vulneratio uteri：Uterus is exposed, aseptic syringe needle is taken and is stabbed uterus side cornua uteri centre position, about 5-6 pins are finished
Abdomen, sterilization belly art area are closed in layering afterwards.
2) with alleviating or improve the probiotic composition of pelvic inflammation to each internal organ index of pelvic infecton model mice
Influence
From the mouse of above modeling, in being randomly divided into blank control group (being left intact), sham-operation group after 7d (only
Do abdominal, do not process uterus), model group, probiotic group (prepared by embodiment 3) (5.0 × 108Cfu/d), probiotics Chinese medicine
Group (prepared by embodiment 4) (0.025g/d), product group (prepared by embodiment 5) (0.03g/d), commercially available prod group (0.037g/d),
Every group 10；In addition to the pure water that blank, sham-operation group and model group such as give at the capacity, remaining gives receives accordingly
Test agent, continuous gavage 21d.
It is discontinued next day, mouse weights take serum and put to death, takes liver, thymus gland, uterus after dissection respectively and weigh, and uterus
Fixed with 4% neutral formalin fixer, FFPE, conventional section.HE is dyeed, and light Microscopic observation uterus Pathomorphology becomes
Change.
Table 1：Influence (x ± s, n=10) to the prebiotic function of mice viscera index
Note：A, b, c represent significant difference (0.01<P<0.05).
As shown in Table 1, uterus index can be seen that model group has obvious swelling compared with blank control group, and swelling degree is improved
23.6%, illustrate that modeling is successful；Probiotics Chinese medicine group, product group and commercially available prod group are compared with model group uterus in given the test agent
Swelling degree is respectively provided with obvious improvement, and swelling degree reduces by 12.1%, 18.0% and 17.5% respectively, illustrates probiotics with
Medicine combination application effect improves significantly compared with probiotic effect, and product effect prepared by embodiment 5 is more preferably, illustrates the present invention
The product of preparation has some improvement to the symptom tool of pelvic infecton；Thymus index can be seen that model group has compared with sham-operation group
Variant conspicuousness, but there is no the significance of difference with other each groups, illustrate the inflammatory reaction of model group shadow to a certain extent
Thymus index is rung, it is increased compared with blank control group；Liver index can be seen that model group is variant compared with test sample group aobvious
Work property, and tested group of liver index reduction, illustrate probiotic composition of the invention, probiotics Chinese medicine preparation and product to liver
It is safe without infringement or toxic action.
3) with uterus pathological change of the probiotic composition to pelvic infecton model mice for alleviating or improving pelvic inflammation
Influence
Uterus pathology observation index and ranking criterion are：(1) Asherman's syndrom locking or expansion："-" remembers 0 point without lesion；
The lesions of "+" ＜ 1/3 remember 1 point；" ++ " 1/3-2/3 lesion remembers 2 points；" +++ " more than 2/3 lesion remembers 3 points.(2) cavity wall structure disease
Become：Each Rotating fields of "-" normally remember 0 point；"+" mucosa lamina propria gland structure disappears and remembers 1 point；" ++ " muscle layer is demarcated with mucous layer
Unclear 2 points of note；Unclear 3 points of the note of " +++ " hierarchy.(3) epithelial cell degeneration necrosis："-" simple columnar epithelium remembers 0 point；
"+" epithelial cell is flat or the ＜ 1/3 that comes off remembers 1 point；" ++ " epithelial cell is flat or 1/3-2/3 lesion that comes off remembers 2 points；“+++”
Holostrome epithelial cell degeneration necrosis remember 3 points.(4) chronic cell infiltration："-" remembers 0 point without chronic cell infiltration；"+" decimal
It is dispersed in or stove and 1 point of the note only in mucosa lamina propria；" ++ " be dispersed in or stove but go deep into muscle layer remember 2 points；" +++ " majority is dispersed in
Or stratiform infiltrates and involves holostrome and remembers 3 points.(5) inner membrance congestion and edema："-" remembers 0 point without inner membrance congestion and edema；"+" lamina propria is light
Micro- congestion and edema remembers 1 point；" ++ " substantially congestion and edema remembers 2 points；" +++ " holostrome congestion and edema remembers 3 points.
Table 2：Influence to mouse pelvic infecton model uterus pathological change (appraisal result) caused by mechanical damage
Model success rate may be up to more than 90% as shown in Table 2, and the lesion degree for being only given the model group uterus of pure water is tight
Weight；Product and commercially available prod prepared by probiotic composition, probiotics Chinese medicine preparation, embodiment 5 can be obviously improved uterus
Lesion degree, product effect prepared by embodiment 5 preferably, can compare favourably with commercially available prod, make the reduction of its lesion degree
65.5%.
4) with alleviate or improve pelvic inflammation probiotic composition to pelvic infecton model mice Serum Indexes cell because
The influence table 3 of son：Influence (x ± s, n=10) to the mouse pelvic infecton model Serum Indexes cell factor caused by mechanical damage
Note：A, b, c represent significant difference (0.01<P<0.05).
As shown in Table 3, IL-2 model groups are compared with blank control group content reduction by 6.20%；IL-6 and TNF-α model group are more empty
White control group content is respectively increased has the significance of difference between 9.1% and 11.2%, and two groups of the content of TNF-α, explanation is made
Mould success.After giving given the test agent, the content of IL-2 is raised, product prepared by probiotic group, probiotics Chinese medicine group, embodiment 5
Condition improves 4.73%, 20.6%, 26.2% for model group successively, although comparing without significant difference with commercially available prod group
Property, but it is better than commercially available prod group effect,；The content probiotics Chinese medicine group and product group of IL-6 are respectively provided with difference and show compared with other groups
Work property, two groups reduce by 15.6% and 25.7% respectively compared with model group content, and product group is compared with the group of commercially available prod, and content shows
Writing reduces by 21.8%, illustrates that product effect prepared by embodiment 5 is better than commercially available prod, has to pelvic inflammation and is obviously improved work
With；The content each group of TNF-α decreases, and product group effect prepared by embodiment 5 is most obvious, has compared with other each groups
The significance of difference, relative to model group content reduction by 23.2%；Data above illustrates probiotic composition of the invention to pelvic cavity
Inflammation has improvement result, after probiotics, Chinese medicine and prebiotics are used cooperatively, with significant synergy, and one
Determine effect in degree and be better than commercially available prod, show probiotic composition of the invention, probiotics Chinese medicine preparation and product to serum
The content of middle cell factor has active influence, can weaken the inflammatory reaction that pelvic infecton causes, while strengthening the immune anti-of body
Should, illustrate that probiotic composition of the invention, probiotics Chinese medicine preparation and product are effective to alleviating improvement pelvic infecton symptom
's.
The preferred embodiment of the application is the foregoing is only, the application is not limited to, for the skill of this area
For art personnel, the application can have various modifications and variations.It is all within spirit herein and principle, made any repair
Change, equivalent, improvement etc., should be included within the protection domain of the application.
Claims (10)
1. it is a kind of alleviate or improve pelvic inflammation probiotic composition, it is characterised in that by Lactobacillus rhamnosus, acidophilus breast bar
Bacterium and Lactobacillus plantarum are constituted；
In the probiotic composition, the total quantity of probiotics is 8.0 × 109-4.0×1010cfu/g。
2. probiotic composition as claimed in claim 1, it is characterised in that in the probiotic composition, rhamnose breast bar
The mass ratio of bacterium, lactobacillus acidophilus and Lactobacillus plantarum is 2:1:1.
3. probiotic composition as claimed in claim 1, it is characterised in that the lactobacillus acidophilus is deposit number CCTCC
NO:Lactobacillus acidophilus (Lactobacillus acidophilus) BLCC2-0024 of M2015129；The Lactobacillus plantarum is
The Lactobacillus plantarum LP of deposit number CCTCC M2010150.
4. the preparation method of the probiotic composition described in any one of claim 1-3, it is characterised in that step is as follows：
(1) after Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum being activated through culture medium respectively, it is inoculated in fermented and cultured
In liquid, quiescent culture makes cell concentration reach exponential phase 4.0 × 109-8.0×109cfu/ml；
(2) zymotic fluid is centrifuged respectively, abandons supernatant, obtain the bacterium mud of Lactobacillus rhamnosus, lactobacillus acidophilus and Lactobacillus plantarum；
(3) bacterium mud is well mixed with freeze drying protectant, freeze-drying is obtained final product.
5. it is a kind of alleviate or improve pelvic inflammation probiotics Chinese medicine preparation, it is characterised in that as prebiotic described in claim 1
Bacteria composition and the integration of drinking and medicinal herbs Chinese medical extract synergistic combination with treatment pelvic infecton effect are formed；
The integration of drinking and medicinal herbs Chinese medical extract is made up of the bulk drug of following weight portion：
Radix Angelicae Sinensis 2-3 parts, peach kernel 2-5 parts, raw hawthorn 6-12 parts, Poria cocos 10-15 parts, Chinese cassia tree 2-3 parts, Radix Glycyrrhizae 3-9 parts, rose 3-
10 parts, dandelion 6-10 parts, cordate houttuynia 15-30 parts.
6. probiotics Chinese medicine preparation according to claim 5, it is characterised in that the integration of drinking and medicinal herbs Chinese medical extract by with
The bulk drug of lower weight portion is made：
2 parts of Radix Angelicae Sinensis, 3 parts of peach kernel, 8 parts of raw hawthorn, 10 parts of Poria cocos, 2 parts of Chinese cassia tree, 6 parts of Radix Glycyrrhizae, 6 parts of rose, 6 parts of dandelion, fish
15 parts of raw meat grass.
7. alleviation according to claim 5 or 6 or the probiotics Chinese medicine preparation of improvement pelvic inflammation, it is characterised in that institute
Integration of drinking and medicinal herbs Chinese medical extract is stated to be prepared from by the following method：
Radix Angelicae Sinensis, peach kernel, raw hawthorn, Poria cocos, Chinese cassia tree, Radix Glycyrrhizae, rose, dandelion, cordate houttuynia are placed in 8-10 times of water and are soaked
30-60min, decocts, and water continues to decoct 20-40min after opening, and is filtrated to get the first filtrate；The dregs of a decoction carry out secondary decocting with 6-8 times of water
Boil, water continues to decoct 20-40min after opening, and is filtrated to get the second filtrate and is well mixed with the first filtrate, is concentrated into solid content
It is more than 30%, spray drying is crushed, sieving obtains final product integration of drinking and medicinal herbs Chinese medical extract.
8. probiotics Chinese medicine preparation according to claim 5, it is characterised in that the probiotic composition and integration of drinking and medicinal herbs
The weight ratio of Chinese medical extract is (2-10)：(20-30).
9. in the probiotics described in probiotic composition described in any one of claim 1-3 and/or claim any one of 5-7
Purposes of the medicine preparation in the product alleviated or improve pelvic inflammation is prepared.
10. it is a kind of alleviate or improve pelvic inflammation product, it is characterised in that be made up of the component of following mass percent：
Probiotic composition 2-10%, integration of drinking and medicinal herbs Chinese medical extract 20-30%, prebiotics 50-60%, auxiliary material filler 5-
10%；
The prebiotics is selected from one or more in oligoisomaltose, FOS and xylo-oligosaccharide；Preferably, the benefit
Raw unit is by oligoisomaltose, FOS and xylo-oligosaccharide in mass ratio 5:3:1 composition；
The auxiliary material filler is selected from one or more in maltodextrin, citric acid, fruit powder and sugar alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710141644.6A CN106692204B (en) | 2017-03-10 | 2017-03-10 | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710141644.6A CN106692204B (en) | 2017-03-10 | 2017-03-10 | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106692204A true CN106692204A (en) | 2017-05-24 |
| CN106692204B CN106692204B (en) | 2020-05-22 |
Family
ID=58916894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710141644.6A Active CN106692204B (en) | 2017-03-10 | 2017-03-10 | Probiotics composition for relieving or improving pelvic inflammation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106692204B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108338993A (en) * | 2018-02-02 | 2018-07-31 | 云南中京国建投资有限公司 | A kind of symphysis unit composition of conditioning female reproductive health and its preparation and application |
| CN108902981A (en) * | 2018-04-25 | 2018-11-30 | 深圳市多微生保健食品有限公司 | A kind of probiotic composition and probiotics solid beverage |
| RU2679421C1 (en) * | 2018-02-12 | 2019-02-08 | Государственное научное учреждение Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии Российской академии сельскохозяйственных наук (ГНУ ВНИВИПФиТ Россельхозакадемии) | Method of prevention of inflammatory pathology in reproductive system of sows |
| CN110771766A (en) * | 2019-11-13 | 2020-02-11 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for treating child intestinal colic and diarrhea and repairing intestinal tract |
| CN110917174A (en) * | 2018-09-20 | 2020-03-27 | 广东怡和科洁科技有限公司 | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof |
| CN113116919A (en) * | 2019-12-26 | 2021-07-16 | 儒医(北京)科技有限公司 | Traditional Chinese medicine micro-ecological compound preparation for resisting HPV and HSV and preparation method thereof |
| CN113736695A (en) * | 2021-08-24 | 2021-12-03 | 上海市第一人民医院 | Probiotic strain for improving intestinal barrier function and application thereof |
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233474A (en) * | 1998-04-30 | 1999-11-03 | 勒内塔·玛利亚·安娜·卡瓦利雷·韦德·韦塞利 | Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections |
| CN101401638A (en) * | 2008-10-17 | 2009-04-08 | 东北农业大学 | Method for preparing edible mushroom synbiotics microcapsule |
| CN104147209A (en) * | 2014-08-27 | 2014-11-19 | 上海市青浦区中医医院 | Medicine for treating chronic pelvic inflammatory disease and application thereof |
| CN104519866A (en) * | 2011-01-28 | 2015-04-15 | 益生菌股份公司 | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections |
| EP3030318A1 (en) * | 2013-07-18 | 2016-06-15 | Amino Up Chemical Co., Ltd. | A composition having a prebiotic effect |
-
2017
- 2017-03-10 CN CN201710141644.6A patent/CN106692204B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233474A (en) * | 1998-04-30 | 1999-11-03 | 勒内塔·玛利亚·安娜·卡瓦利雷·韦德·韦塞利 | Pharmaceutical compositions containing lactobacilli for treatment of vaginal infections |
| CN101401638A (en) * | 2008-10-17 | 2009-04-08 | 东北农业大学 | Method for preparing edible mushroom synbiotics microcapsule |
| CN104519866A (en) * | 2011-01-28 | 2015-04-15 | 益生菌股份公司 | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections |
| EP3030318A1 (en) * | 2013-07-18 | 2016-06-15 | Amino Up Chemical Co., Ltd. | A composition having a prebiotic effect |
| CN104147209A (en) * | 2014-08-27 | 2014-11-19 | 上海市青浦区中医医院 | Medicine for treating chronic pelvic inflammatory disease and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 周文静: "益生菌与食药同源中草药协同作用的研究", 《万方数据知识服务平台》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108338993A (en) * | 2018-02-02 | 2018-07-31 | 云南中京国建投资有限公司 | A kind of symphysis unit composition of conditioning female reproductive health and its preparation and application |
| RU2679421C1 (en) * | 2018-02-12 | 2019-02-08 | Государственное научное учреждение Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии Российской академии сельскохозяйственных наук (ГНУ ВНИВИПФиТ Россельхозакадемии) | Method of prevention of inflammatory pathology in reproductive system of sows |
| CN108902981A (en) * | 2018-04-25 | 2018-11-30 | 深圳市多微生保健食品有限公司 | A kind of probiotic composition and probiotics solid beverage |
| CN110917174A (en) * | 2018-09-20 | 2020-03-27 | 广东怡和科洁科技有限公司 | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof |
| CN110771766A (en) * | 2019-11-13 | 2020-02-11 | 上海英库商务咨询有限公司 | Probiotic health-care beverage for treating child intestinal colic and diarrhea and repairing intestinal tract |
| CN113116919A (en) * | 2019-12-26 | 2021-07-16 | 儒医(北京)科技有限公司 | Traditional Chinese medicine micro-ecological compound preparation for resisting HPV and HSV and preparation method thereof |
| CN113736695A (en) * | 2021-08-24 | 2021-12-03 | 上海市第一人民医院 | Probiotic strain for improving intestinal barrier function and application thereof |
| CN113736695B (en) * | 2021-08-24 | 2023-02-03 | 上海市第一人民医院 | Probiotic strain for improving intestinal barrier function and application thereof |
| CN114921389A (en) * | 2022-07-20 | 2022-08-19 | 广东益可维生物技术有限公司 | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106692204B (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692204A (en) | Probiotics composition for alleviating or improving pelvic inflammatory diseases and preparation method thereof | |
| CN102145111B (en) | Traditional Chinese medicine composition for treating colpitis mycotica and preparation method thereof | |
| CN103734428B (en) | A kind of glossy privet fruit health-care tea improving immunity and preparation method thereof | |
| KR101646156B1 (en) | Fermented foods improve bowel function and a method of manufactuing stercoral removal efficacy | |
| CN112568324B (en) | Composite probiotics fermented traditional Chinese medicine feed additive and preparation method and application thereof | |
| CN106581360A (en) | Probiotic fermented Chinese herbal medicine compound preparation for improving milk quality of sows and preparation method thereof | |
| CN106265763A (en) | There is slow down aging and the compositions of skin-care functional and application thereof | |
| CN102600443B (en) | Combination capable of improving immunity and preparation method and application | |
| CN114921389A (en) | Probiotic composition with female intestinal private part nursing and mammary gland anti-inflammatory effects and application thereof | |
| CN103800772A (en) | Gynecological external lotion for preventing and treating vagina inflammatory diseases and preparation method thereof | |
| WO2018188525A1 (en) | Composition for use in improving circulation in body and delaying aging as well as use thereof | |
| CN106924477B (en) | Composite traditional Chinese medicine fermentation preparation produced by mixed bacteria fermentation and preparation method thereof | |
| CN106798755A (en) | A kind of probiotic composition and its application with conditioning breast hyperplasia function | |
| CN105707463A (en) | Enteromorpha feed for dairy cattle and preparation method thereof | |
| CN105274032B (en) | A kind of antagonism campylobacter jejuni and the lactobacillus reuteri for inhibiting its flaA gene expression | |
| CN106974278A (en) | A kind of prostate nutrient powder and its preparation method and application | |
| CN107693551A (en) | Compound ferment bath composition and its fermentation process and application | |
| CN115887535B (en) | Compound Chinese medicinal residue fermentation liquor for preventing and treating colibacillosis of poultry and preparation method thereof | |
| CN106361910A (en) | Liquid Chinese herbal biological feed additive and preparation method thereof | |
| CN105727253A (en) | Liver protecting and toxin removing composition for prevention and treatment of liver diseases and relevant metabolic diseases and preparation method thereof | |
| CN109966427A (en) | A kind of fermentation living bacterial liquid and preparation method thereof treated tumour and improve immunity of organisms | |
| CN107823375A (en) | A kind of Chinese medicinal tablet for treating mastitis for milk cows and preparation method thereof | |
| CN107411014A (en) | A kind of antifatigue milk piece | |
| CN109646546B (en) | A Chinese medicinal composition for preventing and treating diarrhea of livestock, and its preparation method | |
| CN106377700A (en) | Folium mori and bitter gourd tea and making method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180807 Address after: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant after: Tai'an Da Fan Shennong biological Co., Ltd. Address before: 271600 Jinniu Mountain street, Tai'an, Shandong 001 Applicant before: Taian Dafan Shennong Pharmaceutical Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181226 Address after: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Applicant after: Shandong Shennong Hospital Management Co., Ltd. Address before: 271000 Laboratory Building of Shandong Baolai Lilai Bioengineering Co., Ltd. south of Pioneering Street, Eastern New District, Taishan District, Tai'an City, Shandong Province Applicant before: Tai'an Da Fan Shennong biological Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200426 Address after: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Applicant after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Applicant before: Shandong Shennong Hospital Management Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 271000 first floor, No. 17, Huayuan Road, Shanggao street, Taishan District, Tai'an City, Shandong Province Patentee after: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. Address before: 271021 Experimental Building of Shandong Baolailailailailailai Bioengineering Co., Ltd. to the South of Pioneering Street, East New District, Taishan District, Taian City, Shandong Province Patentee before: TAIAN DAFAN SHENNONG BIOLOGY Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |